Physician profile
John Hall
NPI 1841295649
$803.63
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $27.49 · 2021: $311 · 2022: $153.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.67 | 2019-2022 | |
| Lilly USA, LLC | $108.93 | 2019 | |
| Janssen Biotech, INC. | $73.67 | 2019-2022 | |
| Genzyme Corporation | $63.28 | 2019-2020 | |
| Pfizer INC. | $55.19 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $50.53 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $50.48 | 2021 | |
| Amgen INC. | $26.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.36 | 2021 | |
| Galderma Laboratories, L.P. | $14.81 | 2022 | |
| Boston Scientific Corporation | $13.91 | 2021 | |
| Biofrontera INC. | $13.15 | 2022 | |
| Journey Medical Corporation | $12.35 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.